|
gptkbp:instanceOf
|
gptkb:drug
stimulant
|
|
gptkbp:administeredBy
|
adolescents
adults
children
|
|
gptkbp:approvedBy
|
1955
|
|
gptkbp:ATCCode
|
N06BA04
|
|
gptkbp:brand
|
gptkb:Daytrana
gptkb:Quillivant_XR
gptkb:Ritalin
gptkb:Concerta
Metadate
|
|
gptkbp:CASNumber
|
113-45-1
|
|
gptkbp:chemicalClass
|
piperidine
|
|
gptkbp:chemicalFormula
|
methyl 2-phenyl-2-(piperidin-2-yl)acetate
|
|
gptkbp:contraindication
|
glaucoma
Tourette syndrome
severe anxiety
tics
|
|
gptkbp:developedBy
|
gptkb:Switzerland
|
|
gptkbp:discoveredBy
|
gptkb:Leandro_Panizzon
|
|
gptkbp:discoveredIn
|
1944
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C14H19NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Methylphenidate
|
|
gptkbp:legalStatus
|
prescription only
Schedule II controlled substance (US)
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
dopamine reuptake inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
gptkb:arrhythmia
vomiting
hypertension
delirium
hyperthermia
hallucinations
agitation
tremors
convulsions
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:relatedTo
|
gptkb:dexmethylphenidate
cocaine
amphetamine
|
|
gptkbp:riskFactor
|
abuse
dependence
|
|
gptkbp:routeOfAdministration
|
oral
transdermal
|
|
gptkbp:sideEffect
|
headache
loss of appetite
increased heart rate
nervousness
insomnia
dry mouth
|
|
gptkbp:usedFor
|
gptkb:attention_deficit_hyperactivity_disorder
narcolepsy
|
|
gptkbp:bfsParent
|
gptkb:Schedule_II
gptkb:Schedule_II_(US)
|
|
gptkbp:bfsLayer
|
6
|